Franciscan Health Cancer Center Indianapolis

Indianapolis, IN

Sorting 2 by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Not yet accepting

MagnetisMM-15

Elranatamab Post Trial Access: An Open-Label, Single-Arm Study For Participants with Multiple Myeloma Continuing From Pfizer-Sponsored Elranatamab Clinical Studies
Learn more
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 4
1 hidden based on your filters. Show All